Clinical Approach to Menstrual Change
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of menstrual change
Menstrual changes are among the most common presenting complaints in women of reproductive age, accounting for approximately 20% of gynecological consultations. Abnormal uterine bleeding affects up to 30% of women during their reproductive years, with prevalence increasing to nearly 50% in the perimenopausal period. Heavy menstrual bleeding alone impacts 10-35% of women worldwide and is a leading cause of iron deficiency anemia. Understanding the spectrum of menstrual abnormalities is essential for all clinicians, as these changes may signal benign hormonal fluctuations or indicate serious underlying pathology requiring urgent intervention.
Definition
Menstrual change refers to any deviation from a woman’s normal menstrual pattern, including alterations in cycle length (frequency), duration of bleeding, volume of blood loss, or regularity. A normal menstrual cycle ranges from 24 to 38 days in length, with menstrual bleeding lasting 4 to 8 days and blood loss of 5 to 80 milliliters per cycle. Any persistent deviation from these parameters or from an individual’s established baseline warrants clinical evaluation.
Normal Menstrual Parameters
| Parameter | Normal Range | Clinical Notes |
|---|---|---|
| Cycle Length | 24 to 38 days | Measured from first day of one period to first day of next |
| Cycle Regularity | Variation of ≤7-9 days cycle to cycle | Greater variation suggests anovulation |
| Duration of Bleeding | 4 to 8 days | Bleeding beyond 8 days is prolonged |
| Volume of Blood Loss | 5 to 80 milliliters | Difficult to quantify; assess by impact on quality of life |
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Single episode or less than 3 months | Pregnancy complications, infection, medication effects, acute stress | Rule out pregnancy first; may be self-limiting or require urgent intervention |
| Subacute | 3 to 6 months | Hormonal contraception initiation, thyroid dysfunction, early perimenopause | Warrants investigation if persisting; may still represent adjustment period |
| Chronic | Greater than 6 months | Structural lesions (fibroids, polyps), polycystic ovary syndrome, adenomyosis, coagulopathy | Requires systematic evaluation; higher likelihood of identifiable pathology |
Classification by Character of Change
Changes in Frequency
Amenorrhea: Absence of menstruation. Primary amenorrhea is failure to menstruate by age 15 with secondary sexual characteristics (or by age 13 without). Secondary amenorrhea is absence of menses for 3 or more months in previously menstruating women.
Oligomenorrhea: Infrequent menstruation with cycles longer than 38 days. Often associated with anovulation and conditions such as polycystic ovary syndrome.
Polymenorrhea: Frequent menstruation with cycles shorter than 24 days. May indicate luteal phase defect or anovulatory cycles.
Changes in Volume
Heavy Menstrual Bleeding (Menorrhagia): Excessive blood loss exceeding 80 milliliters per cycle, or bleeding that interferes with physical, social, or emotional quality of life. Practical indicators include soaking through a pad or tampon every hour for several consecutive hours, passing clots larger than a 50-pence coin, or needing to use double protection.
Hypomenorrhea: Abnormally light menstrual flow, often lasting less than 2 days. May indicate outflow obstruction (Asherman syndrome), hormonal insufficiency, or be a normal variant.
Changes in Timing and Pattern
Intermenstrual Bleeding (Metrorrhagia): Bleeding occurring between expected menstrual periods. Warrants investigation for cervical or endometrial pathology.
Irregular Bleeding: Unpredictable timing of menstruation with variation greater than 9 days cycle-to-cycle. Commonly seen in anovulatory states.
Combined Patterns
Menometrorrhagia: Heavy bleeding occurring at irregular intervals, combining features of menorrhagia and metrorrhagia. Often indicates significant underlying pathology.
Postcoital Bleeding: Bleeding after sexual intercourse. Requires evaluation for cervical pathology including malignancy.
Classification by Pattern and Associated Features
| Pattern | Description | Suggests |
|---|---|---|
| Regular but Heavy | Predictable cycle timing with excessive flow | Structural causes: fibroids, adenomyosis, polyps; coagulopathy |
| Irregular and Heavy | Unpredictable timing with excessive flow | Anovulation, endometrial hyperplasia, malignancy |
| Infrequent with Hyperandrogenism | Oligomenorrhea with acne, hirsutism, or alopecia | Polycystic ovary syndrome, late-onset congenital adrenal hyperplasia |
| Absent with Galactorrhea | Amenorrhea with inappropriate milk production | Hyperprolactinemia: pituitary adenoma, medication effect |
| Progressive Shortening with Vasomotor Symptoms | Decreasing cycle length, hot flashes, night sweats | Perimenopause, premature ovarian insufficiency |
| Cyclic Pain with Heavy Bleeding | Severe dysmenorrhea worsening over time | Adenomyosis, endometriosis |
The PALM-COEIN Classification System
Key Concept: The International Federation of Gynecology and Obstetrics (FIGO) developed the PALM-COEIN classification to standardize the categorization of abnormal uterine bleeding causes. This system divides causes into Structural (PALM) and Non-structural (COEIN) categories, providing a systematic framework for evaluation.
PALM — Structural Causes
- P — Polyp (endometrial or cervical)
- A — Adenomyosis
- L — Leiomyoma (fibroids: submucosal vs other)
- M — Malignancy and hyperplasia
Structural causes are typically identifiable on imaging or histopathology.
COEIN — Non-structural Causes
- C — Coagulopathy
- O — Ovulatory dysfunction
- E — Endometrial (primary disorders of hemostasis)
- I — Iatrogenic (medications, devices)
- N — Not otherwise classified
Non-structural causes require laboratory or clinical assessment.
Impact on Quality of Life
Clinical Pearl
The impact of menstrual changes on a woman’s quality of life is often more clinically relevant than absolute measurements. Heavy menstrual bleeding is now defined by NICE guidelines as “excessive menstrual blood loss which interferes with a woman’s physical, social, emotional, and/or material quality of life.” Always ask about the effect on daily activities, work, social functioning, and emotional wellbeing when assessing significance.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of menstrual change
Normal menstruation is a finely orchestrated process requiring intact anatomy, a functioning hypothalamic-pituitary-ovarian (HPO) axis, a responsive endometrium, and normal hemostatic mechanisms. Disruption at any level of this system can result in menstrual abnormalities. Understanding these mechanisms is essential for targeted diagnosis and management, as the underlying cause directly influences treatment selection.
The Hypothalamic-Pituitary-Ovarian Axis
| Component | Structure | Function |
|---|---|---|
| Hypothalamus | Arcuate nucleus, median eminence | Secretes gonadotropin-releasing hormone (GnRH) in pulsatile fashion; integrates signals from higher brain centers and metabolic status |
| Anterior Pituitary | Gonadotroph cells | Produces follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in response to GnRH; regulated by ovarian feedback |
| Ovaries | Follicles, corpus luteum, stroma | Produce estrogen and progesterone; undergo follicular development, ovulation, and luteinization |
| Endometrium | Functional and basal layers | Proliferates under estrogen influence; undergoes secretory transformation under progesterone; sheds when hormonal support withdrawn |
Phases of the Normal Menstrual Cycle
Follicular Phase
Duration: Variable (typically 10-14 days)
Hormones: Rising FSH stimulates follicular development; dominant follicle produces increasing estrogen
Endometrium: Proliferative phase — estrogen drives endometrial thickening and glandular growth
Ovulation
Duration: Approximately 24-36 hours
Trigger: LH surge in response to sustained high estrogen levels
Events: Follicular rupture, oocyte release, corpus luteum formation begins
Luteal Phase
Duration: Relatively fixed at 14 days (±2 days)
Hormones: Corpus luteum produces progesterone and estrogen
Endometrium: Secretory transformation — glands become tortuous, stroma decidualizes
Mechanism of Normal Menstruation
The Progesterone Withdrawal Model: Menstruation occurs when the corpus luteum regresses in the absence of pregnancy, leading to withdrawal of progesterone support. This triggers a cascade of events including vasoconstriction of spiral arterioles, tissue ischemia, release of prostaglandins and matrix metalloproteinases, and ultimately, controlled shedding of the functional endometrial layer.
| Phase | Mechanism | Clinical Relevance |
|---|---|---|
| Vasoconstriction | Spiral arteriole spasm due to prostaglandin F2α and endothelin-1 | Limits blood loss; dysfunction leads to heavy bleeding |
| Tissue Breakdown | Matrix metalloproteinases degrade extracellular matrix | Allows orderly shedding of functional layer |
| Hemostasis | Platelet plug formation, fibrin deposition, and fibrinolysis | Coagulopathies cause heavy or prolonged bleeding |
| Regeneration | Re-epithelialization from basal layer within 48 hours | Endometrial damage (Asherman syndrome) impairs this process |
How Different Conditions Cause Menstrual Change
Structural Causes (PALM)
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Uterine Fibroids (Leiomyomata) | Submucosal fibroids distort the endometrial cavity, increase surface area for bleeding, and interfere with normal myometrial contraction; may also cause venous congestion | Location determines bleeding risk — submucosal fibroids cause most bleeding; surgical or medical management based on location and size |
| Endometrial Polyps | Localized overgrowth of endometrial tissue with abnormal vasculature; fragile surface prone to bleeding; may be hormone-sensitive | Hysteroscopic polypectomy is curative; exclude malignancy especially in postmenopausal women |
| Adenomyosis | Endometrial glands and stroma invade the myometrium, causing uterine enlargement, impaired contractility, and increased prostaglandin production | Often coexists with endometriosis; responds to hormonal suppression; definitive treatment is hysterectomy |
| Endometrial Hyperplasia/Malignancy | Unopposed estrogen stimulation leads to abnormal endometrial proliferation; progressive atypia can develop into carcinoma | Risk factors include obesity, anovulation, tamoxifen use; requires histological diagnosis and staging |
Non-Structural Causes (COEIN)
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Ovulatory Dysfunction | Anovulation results in continuous estrogen exposure without progesterone opposition, leading to irregular endometrial shedding and unstable, thickened endometrium | Treat underlying cause (polycystic ovary syndrome, thyroid disease, hyperprolactinemia); cyclic progestins or combined hormonal contraceptives restore cycle |
| Coagulopathy | Inherited or acquired bleeding disorders impair normal hemostasis during menstruation; von Willebrand disease is most common | Screen all adolescents with heavy menses from menarche; treatment includes antifibrinolytics, desmopressin, or factor replacement |
| Endometrial Disorders | Primary defects in local endometrial hemostasis including abnormal prostaglandin ratios, increased fibrinolysis, or deficient vasoconstriction | Diagnosis of exclusion; responds to tranexamic acid, NSAIDs, or levonorgestrel intrauterine system |
| Iatrogenic Causes | Anticoagulants impair clotting; hormonal contraceptives alter endometrial stability; intrauterine devices may cause mechanical irritation | Review medication list; adjust anticoagulation if safe; reassurance for initial breakthrough bleeding on contraceptives |
Hormonal Mechanisms of Menstrual Disturbance
Thyroid Disorders
Hypothyroidism: Causes heavy, prolonged, or frequent periods through altered sex hormone-binding globulin levels, impaired metabolism of estrogen, and sometimes hyperprolactinemia.
Hyperthyroidism: Often causes light or infrequent periods through accelerated hormone metabolism and effects on gonadotropin secretion.
Hyperprolactinemia
Mechanism: Elevated prolactin inhibits pulsatile GnRH secretion, leading to hypogonadotropic hypogonadism.
Result: Oligomenorrhea progressing to amenorrhea; may present with galactorrhea.
Causes: Pituitary adenoma, medications (antipsychotics, metoclopramide), hypothyroidism.
Polycystic Ovary Syndrome
Mechanism: Hyperandrogenism disrupts follicular development, causing chronic anovulation. Peripheral conversion of androgens to estrogen provides unopposed estrogen stimulation to endometrium.
Result: Irregular, often infrequent periods with episodes of heavy bleeding; increased risk of endometrial hyperplasia.
Premature Ovarian Insufficiency
Mechanism: Accelerated follicular depletion or destruction leads to estrogen deficiency and elevated gonadotropins before age 40.
Result: Oligomenorrhea progressing to amenorrhea, often with vasomotor symptoms and signs of hypoestrogenism.
Often Overlooked Mechanism
Obesity and Estrogen Conversion: Adipose tissue contains aromatase enzyme that converts androgens to estrogens. In obese women, this peripheral estrogen production can lead to chronic anovulation and unopposed estrogen exposure to the endometrium, significantly increasing the risk of endometrial hyperplasia and carcinoma — even in young women. This mechanism explains why obesity is one of the strongest risk factors for endometrial cancer and why weight loss can restore ovulatory cycles.
Endometrial Hemostasis: The Local Control System
Normal menstruation involves sophisticated local hemostatic mechanisms that limit blood loss. Understanding these mechanisms explains why some women experience heavy bleeding despite normal systemic coagulation.
| Component | Normal Function | When Disrupted |
|---|---|---|
| Prostaglandins | Balance of vasoconstrictors (prostaglandin F2α) and vasodilators (prostaglandin E2, prostacyclin) | Increased prostaglandin E2/prostacyclin ratio leads to vasodilation and heavy bleeding; explains efficacy of NSAIDs |
| Endothelin-1 | Potent vasoconstrictor released during menstruation | Deficiency contributes to heavy menstrual bleeding |
| Tissue Factor | Initiates coagulation cascade locally | Reduced expression leads to impaired clot formation |
| Fibrinolysis | Plasminogen activators normally balanced by inhibitors | Excessive fibrinolysis dissolves clots prematurely; tranexamic acid counteracts this |
Integration of Mechanisms
In clinical practice, multiple mechanisms often coexist. For example, a woman with polycystic ovary syndrome may have anovulation (ovulatory dysfunction) leading to unopposed estrogen exposure, combined with obesity-related peripheral estrogen production, resulting in an unstable, thickened endometrium prone to irregular, heavy bleeding. Additionally, she may develop endometrial polyps (structural cause). Successful management requires addressing all contributing factors.
3. History Taking
A comprehensive approach to eliciting the menstrual change history
Red Flags — Require Urgent Evaluation
- Postmenopausal bleeding — Endometrial malignancy until proven otherwise
- Hemodynamic instability — Signs of hypovolemic shock from acute blood loss
- Positive pregnancy test with bleeding — Ectopic pregnancy, miscarriage, molar pregnancy
- Bleeding with fever and pelvic pain — Pelvic inflammatory disease, septic abortion
- New irregular bleeding in women over 45 — Increased risk of endometrial pathology
- Intermenstrual or postcoital bleeding — Cervical malignancy must be excluded
- Heavy bleeding with bruising or mucosal bleeding — Underlying coagulopathy
- Amenorrhea with severe headache or visual changes — Pituitary tumor with mass effect
Systematic History: The “PERIODS” Approach
Use the mnemonic “PERIODS” to ensure comprehensive history taking for menstrual change:
- P — Pattern and Previous Normal: What was your normal cycle like? How has it changed? When did the change begin?
- E — Extent of Bleeding: How heavy is the bleeding? How many pads/tampons per day? Clots? Duration of each period?
- R — Related Symptoms: Pain? Bloating? Breast tenderness? Hot flashes? Discharge? Weight change?
- I — Impact on Life: Missing work or school? Avoiding activities? Needing double protection? Accidents or flooding?
- O — Obstetric and Gynecological History: Pregnancies? Contraception? Last cervical screening? Previous gynecological problems or surgery?
- D — Drugs and Medical History: Medications (especially hormones, anticoagulants)? Thyroid disease? Bleeding disorders? Chronic conditions?
- S — Sexual History and STI Risk: Sexually active? New partners? Possibility of pregnancy? History of sexually transmitted infections?
Establishing the Menstrual Baseline
Essential Questions for Every Patient
- Age at menarche: Late menarche (after 15) may indicate underlying condition
- Date of last menstrual period (LMP): First day of most recent period
- Usual cycle length: Days from start of one period to start of next (normal: 24-38 days)
- Usual duration of bleeding: How many days does bleeding typically last? (normal: 4-8 days)
- Regularity: Can you predict when your period will come? How much does it vary?
- For perimenopausal women: Any changes in pattern over the past year?
Quantifying Menstrual Blood Loss
Objective measurement of blood loss is impractical in clinical settings. Use practical indicators to assess severity:
| Indicator | Questions to Ask | Interpretation |
|---|---|---|
| Product Use | “How many pads or tampons do you use per day? How often do you need to change them?” | Soaking through a pad/tampon hourly for several consecutive hours suggests heavy bleeding |
| Clots | “Do you pass blood clots? How large are they?” | Clots larger than a 50-pence coin (approximately 2.5 cm) indicate heavy flow |
| Double Protection | “Do you need to wear both a pad and tampon at the same time?” | Need for double protection suggests heavy bleeding |
| Night-time Impact | “Do you need to get up at night to change protection? Do you use extra protection at night?” | Nocturnal flooding is a significant indicator of heavy loss |
| Flooding/Accidents | “Have you had any accidents where blood leaked through your clothes?” | Episodes of flooding indicate inadequate containment of flow |
| Anemia Symptoms | “Do you feel tired, short of breath, or lightheaded?” | Symptoms of iron deficiency suggest clinically significant blood loss |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Pregnancy-Related | Amenorrhea followed by bleeding, breast tenderness, nausea | “Is there any chance you could be pregnant? When was your last normal period? Have you had any pregnancy symptoms?” |
| Uterine Fibroids | Heavy, regular periods; pelvic pressure; urinary frequency; constipation | “Do you feel a sense of pressure or fullness in your pelvis? Do you need to urinate frequently or feel constipated?” |
| Adenomyosis | Heavy, painful periods worsening over time; dyspareunia | “Are your periods getting progressively more painful over the years? Do you have pain during intercourse?” |
| Endometrial Polyps | Intermenstrual bleeding, postcoital bleeding, irregular spotting | “Do you have any bleeding between periods or after sex? Any irregular spotting?” |
| Polycystic Ovary Syndrome | Irregular, infrequent periods; weight gain; acne; excess hair growth | “Have you noticed increased facial or body hair? Acne that started or worsened as an adult? Difficulty losing weight?” |
| Thyroid Dysfunction | Weight change, fatigue, temperature intolerance, hair/skin changes | “Have you noticed changes in your weight, energy levels, or tolerance to hot or cold temperatures?” |
| Hyperprolactinemia | Amenorrhea or oligomenorrhea, galactorrhea, headache, visual changes | “Have you noticed any milk discharge from your nipples when not breastfeeding? Any headaches or changes in vision?” |
| Coagulopathy | Heavy periods since menarche, easy bruising, prolonged bleeding from cuts, family history | “Have your periods always been heavy since they started? Do you bruise easily? Does anyone in your family have a bleeding disorder?” |
| Premature Ovarian Insufficiency | Oligomenorrhea/amenorrhea before age 40, vasomotor symptoms, vaginal dryness | “Have you noticed hot flashes, night sweats, or vaginal dryness? Did your mother or sisters go through menopause early?” |
| Endometrial Hyperplasia/Cancer | Postmenopausal bleeding, prolonged unopposed estrogen exposure, obesity | “Have you had any bleeding after going through menopause? Have you taken estrogen without progesterone?” |
Medication and Contraceptive History
Medications That Affect Menstruation
- Anticoagulants (warfarin, direct oral anticoagulants, heparin) — Increase menstrual blood loss
- Antipsychotics and metoclopramide — Cause hyperprolactinemia leading to oligomenorrhea/amenorrhea
- Selective serotonin reuptake inhibitors — May increase bleeding through platelet effects
- Corticosteroids (long-term) — Can suppress the hypothalamic-pituitary-ovarian axis
- Chemotherapy agents — May cause premature ovarian insufficiency
- Tamoxifen — Increases risk of endometrial polyps, hyperplasia, and malignancy
- NSAIDs — Generally reduce menstrual blood loss (therapeutic effect)
- Herbal supplements (dong quai, ginseng) — May have estrogenic effects
Contraceptive History
- Combined hormonal contraceptives — Breakthrough bleeding common in first 3 months; may cause lighter, more regular periods
- Progestogen-only pill — Variable bleeding patterns; irregular bleeding common
- Depot medroxyprogesterone acetate — Irregular bleeding initially, then often amenorrhea
- Levonorgestrel intrauterine system — Irregular bleeding for 3-6 months, then typically light or absent periods
- Copper intrauterine device — Often increases menstrual blood loss and duration
- Progestogen implant — Unpredictable bleeding pattern; irregular bleeding common
Key Questions: “What contraception are you using? When did you start it? Has your bleeding pattern changed since starting?”
Social and Lifestyle Factors
Lifestyle Factors
- Weight and recent weight change: Obesity causes anovulation; extreme weight loss causes hypothalamic amenorrhea
- Exercise intensity: Excessive exercise can suppress menstruation
- Diet: Restrictive dieting and eating disorders affect the hypothalamic-pituitary-ovarian axis
- Stress: Psychological stress can cause functional hypothalamic amenorrhea
- Sleep patterns: Shift work and disrupted circadian rhythms may affect cycles
Sexual and Reproductive History
- Sexual activity: Essential for pregnancy risk assessment
- Number of partners: Assesses sexually transmitted infection risk
- Dyspareunia: May indicate endometriosis, adenomyosis, or infection
- Fertility intentions: Guides management approach
- Previous pregnancies and outcomes: Including miscarriages, terminations, ectopic pregnancies
- Previous uterine instrumentation: Dilation and curettage, hysteroscopy (risk of Asherman syndrome)
Relevant Family History
| Family History Element | Relevance |
|---|---|
| Bleeding disorders | Von Willebrand disease and other inherited coagulopathies; autosomal dominant inheritance |
| Uterine fibroids | Familial tendency; 2-3 times increased risk if first-degree relative affected |
| Polycystic ovary syndrome | Strong familial component; sisters have 20-40% risk if sibling affected |
| Early menopause | Premature ovarian insufficiency may be familial; fragile X premutation carriers |
| Endometrial or ovarian cancer | Lynch syndrome (hereditary non-polyposis colorectal cancer) increases endometrial cancer risk |
| Thyroid disease | Autoimmune thyroid disease clusters in families |
4. Physical Examination
A systematic approach for patients presenting with menstrual change
Systematic Framework: Use the “General to Specific” approach for complete examination of patients presenting with menstrual change. Begin with general assessment and vital signs, proceed through relevant systemic examination, and conclude with focused pelvic examination when indicated.
General Inspection
- Appearance and body habitus: Obesity (anovulation, endometrial hyperplasia risk), underweight or cachectic (hypothalamic amenorrhea, malignancy)
- Pallor: Conjunctival, palmar crease, and mucous membrane pallor suggest anemia from chronic blood loss
- Signs of androgen excess: Acne, hirsutism (face, chest, abdomen, thighs), male-pattern alopecia — suggest polycystic ovary syndrome or other hyperandrogenic states
- Signs of hypoestrogenism: Dry skin, fine wrinkles, vaginal atrophy — suggest premature ovarian insufficiency or menopause
- Cushingoid features: Moon face, buffalo hump, striae, central obesity — consider Cushing syndrome
- Acanthosis nigricans: Velvety hyperpigmentation in skin folds — indicates insulin resistance
- Signs of thyroid disease: Goiter, exophthalmos, tremor, skin and hair changes
- Bruising or petechiae: May indicate coagulopathy
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 beats per minute) | May indicate anemia, hypovolemia from acute blood loss, hyperthyroidism, or anxiety |
| Blood Pressure | Hypotension, orthostatic changes | Orthostatic hypotension suggests significant hypovolemia; check lying and standing blood pressure in acute heavy bleeding |
| Temperature | Fever (greater than 38°C) | Suggests infection — pelvic inflammatory disease, endometritis, septic abortion |
| Respiratory Rate | Tachypnea | May indicate compensation for anemia or anxiety; also consider pulmonary embolism if postpartum or post-surgical |
| Body Mass Index | Calculate from height and weight | BMI greater than 30: increased anovulation and endometrial hyperplasia risk; BMI less than 18.5: hypothalamic amenorrhea risk |
Head and Neck Examination
Face and Eyes
- Visual field defects: Bitemporal hemianopia suggests pituitary macroadenoma compressing optic chiasm
- Pallor: Conjunctival pallor indicates anemia
- Facial hair distribution: Terminal hair on upper lip, chin suggests hyperandrogenism
- Moon facies: Rounded face with plethora suggests Cushing syndrome
- Lid lag, exophthalmos: Signs of Graves disease
Thyroid Examination
- Inspection: Visible goiter, asymmetry, scars from previous surgery
- Palpation: Size, consistency, nodules, tenderness
- Diffuse enlargement: Graves disease, Hashimoto thyroiditis
- Nodular enlargement: Multinodular goiter, solitary nodule
- Lymphadenopathy: Check cervical lymph nodes
Breast Examination
- Inspection: Symmetry, skin changes, nipple inversion or discharge
- Galactorrhea: Gentle pressure on nipple to check for discharge; milky discharge suggests hyperprolactinemia
- Breast development: Assess Tanner staging in adolescents with primary amenorrhea
- Masses: Palpate for any lumps or abnormalities
Clinical Pearl: Checking for Galactorrhea
To check for galactorrhea, apply gentle pressure to the breast moving toward the nipple. True galactorrhea produces milky discharge from multiple ducts bilaterally. Single-duct or unilateral discharge, or discharge that is bloody, serous, or green, suggests local breast pathology rather than hyperprolactinemia and warrants different investigation.
Abdominal Examination
Inspection
- Distension: May indicate large pelvic mass (fibroids, ovarian mass) or ascites
- Striae: Purple striae suggest Cushing syndrome; silver striae may be normal or from previous pregnancy
- Surgical scars: Previous cesarean section, laparoscopy, laparotomy — relevant for adhesions, Asherman syndrome risk
- Central obesity: Associated with insulin resistance, polycystic ovary syndrome
- Hair distribution: Male-pattern hair on lower abdomen and thighs suggests hyperandrogenism
Palpation
- Masses: Pelvic masses may be palpable abdominally if large; note size, consistency, mobility, tenderness
- Uterine enlargement: Fibroid uterus may be palpable suprapubically; irregular contour suggests fibroids
- Hepatomegaly: May indicate liver disease affecting estrogen metabolism
- Tenderness: Lower abdominal tenderness suggests pelvic inflammatory disease or other pelvic pathology
Pelvic Examination
Pelvic examination should be performed when clinically indicated, with appropriate consent, chaperoning, and attention to patient comfort. It may be deferred in adolescents who are not sexually active and in whom history suggests a benign cause.
External Genitalia Inspection
- Vulvar atrophy: Pallor, loss of labial fullness suggests hypoestrogenism
- Clitoromegaly: Clitoral enlargement greater than 1 cm suggests virilization from severe hyperandrogenism
- Discharge: Note character — purulent suggests infection
- Lesions: Ulcers, warts, or other abnormalities
- Signs of trauma: Consider non-accidental injury if history inconsistent
Speculum Examination
| Structure | What to Assess | Significance of Findings |
|---|---|---|
| Vaginal walls | Color, moisture, rugae, discharge, lesions | Pale, smooth walls suggest atrophy; purulent discharge suggests infection; masses may be visible |
| Cervix | Position, appearance, lesions, discharge, bleeding | Cervical polyps may be visible; contact bleeding, friability, or visible lesion warrants urgent investigation for malignancy |
| Cervical os | Open or closed; products of conception | Open os with products visible indicates incomplete miscarriage; thread visibility confirms intrauterine device in situ |
| Source of bleeding | Cervical versus uterine origin | Blood coming from cervical os suggests uterine source; bleeding from cervical surface suggests cervical pathology |
Bimanual Examination
| Assessment | Technique | Findings and Significance |
|---|---|---|
| Uterine size | Palpate between examining fingers and abdominal hand | Enlarged uterus: pregnancy, fibroids, adenomyosis; describe in weeks’ size equivalent |
| Uterine contour | Assess shape and regularity | Irregular, lumpy contour suggests fibroids; uniformly enlarged and boggy suggests adenomyosis |
| Uterine mobility | Gently move uterus | Fixed uterus suggests adhesions, endometriosis, or malignancy |
| Uterine tenderness | Note pain on palpation or movement | Tenderness suggests infection (endometritis), adenomyosis, or pregnancy complication |
| Adnexal examination | Palpate lateral to uterus bilaterally | Masses may indicate ovarian pathology or ectopic pregnancy; tenderness suggests infection or torsion |
| Cervical motion tenderness | Gently move cervix side to side | Pain on cervical motion suggests pelvic inflammatory disease (classically described as “chandelier sign”) |
Assessment for Hyperandrogenism
| Sign | Assessment | Scoring/Grading |
|---|---|---|
| Hirsutism | Assess terminal hair in androgen-sensitive areas: upper lip, chin, chest, upper/lower abdomen, upper/lower back, upper arms, thighs | Modified Ferriman-Gallwey score: each area scored 0-4; total ≥8 indicates hirsutism (varies by ethnicity) |
| Acne | Face, chest, and back; note severity and type (comedonal, inflammatory, nodulocystic) | Adult-onset or treatment-resistant acne particularly suggestive of hyperandrogenism |
| Androgenic alopecia | Hair thinning at crown with preservation of frontal hairline (Ludwig pattern) | Ludwig classification I-III based on severity |
| Virilization | Clitoromegaly, deepening voice, male-pattern baldness, increased muscle mass | Suggests severe hyperandrogenism — investigate for androgen-secreting tumor or congenital adrenal hyperplasia |
Expected Physical Findings by Etiology
| Condition | General Examination | Pelvic Examination | Other Findings |
|---|---|---|---|
| Uterine Fibroids | May be normal; pallor if anemic | Enlarged, irregular uterus; may be palpable abdominally if large | Usually none |
| Adenomyosis | May be normal; pallor if anemic | Uniformly enlarged, globular, tender uterus; typically 12-14 weeks’ size maximum | Usually none |
| Endometrial Polyp | Usually normal | Usually normal; polyp may be visible at cervical os if prolapsing | Usually none |
| Polycystic Ovary Syndrome | Obesity, acanthosis nigricans, hirsutism, acne, androgenic alopecia | Usually normal; sometimes slightly enlarged ovaries palpable | Elevated BMI; consider metabolic syndrome features |
| Thyroid Dysfunction | Goiter, tremor, skin changes, altered reflexes | Usually normal | Bradycardia or tachycardia; weight change |
| Hyperprolactinemia | May have visual field defects if pituitary adenoma; galactorrhea | May show signs of hypoestrogenism if prolonged | Galactorrhea on breast examination |
| Premature Ovarian Insufficiency | May show signs of hypoestrogenism | Vaginal atrophy, small uterus | May have features of associated autoimmune conditions |
| Coagulopathy | Bruising, petechiae, mucosal bleeding | Usually normal | Evidence of bleeding at other sites |
| Pelvic Inflammatory Disease | May be febrile, unwell appearance | Cervical motion tenderness, adnexal tenderness, purulent discharge | Fever, tachycardia |
Important Teaching Point
Normal examination is common! Many causes of menstrual change present with entirely normal physical examination findings. Endometrial polyps, small fibroids, ovulatory dysfunction, coagulopathies, early endometrial hyperplasia, and most hormonal causes often have no detectable examination findings. A normal examination does not exclude significant pathology — the diagnosis frequently depends on laboratory investigations and imaging. The examination remains valuable for identifying red flag features, assessing overall health, and detecting conditions that do produce physical signs.
5. Differential Diagnosis
Systematic approach organized by probability, pattern, and clinical features
The differential diagnosis for menstrual change is broad and varies significantly based on the type of change (heavy bleeding versus absent periods versus irregular bleeding), the patient’s age, and reproductive status. Using the PALM-COEIN classification system alongside probability-based thinking allows for systematic evaluation.
Heavy Menstrual Bleeding (Menorrhagia)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 60-70%) | Uterine Fibroids (Leiomyomata) | Regular but heavy periods; pelvic pressure; urinary frequency; enlarged, irregular uterus | Rapid growth; postmenopausal growth (consider leiomyosarcoma) |
| COMMON | Adenomyosis | Heavy, painful periods worsening with age; dyspareunia; uniformly enlarged, tender uterus | Symptoms not improving with standard treatment |
| COMMON | Ovulatory Dysfunction | Irregular timing with variable flow; often at extremes of reproductive age; associated with obesity or polycystic ovary syndrome | Prolonged heavy bleeding; age over 45 (endometrial hyperplasia risk) |
| COMMON | Endometrial Polyps | Intermenstrual bleeding; postcoital bleeding; may have heavy periods; often asymptomatic | Postmenopausal bleeding; polyp greater than 1.5 cm |
| LESS COMMON (approximately 20-30%) | Coagulopathy (von Willebrand disease most common) | Heavy periods since menarche; easy bruising; prolonged bleeding from cuts; family history of bleeding | Severe bleeding requiring transfusion; bleeding at multiple sites |
| LESS COMMON | Iatrogenic (Copper Intrauterine Device) | Heavy periods developing after copper intrauterine device insertion; otherwise regular cycle | Signs of infection; expulsion; pregnancy |
| LESS COMMON | Iatrogenic (Anticoagulant Therapy) | Heavy periods in patient on warfarin, direct oral anticoagulants, or antiplatelet agents | Supratherapeutic anticoagulation; bleeding at other sites |
| UNCOMMON BUT SERIOUS (approximately 5-10%) | Endometrial Hyperplasia | Prolonged, heavy, or irregular bleeding; risk factors: obesity, anovulation, tamoxifen, unopposed estrogen | Postmenopausal bleeding; atypia on biopsy |
| UNCOMMON BUT SERIOUS | Endometrial Carcinoma | Postmenopausal bleeding; abnormal bleeding in high-risk patients; median age 60 years | Any postmenopausal bleeding requires investigation |
Amenorrhea (Absent Menstruation)
Step-by-Step Approach to Amenorrhea:
- Step 1: Always exclude pregnancy first — even if patient reports no sexual activity
- Step 2: Classify as primary (never menstruated) or secondary (cessation after previous menstruation)
- Step 3: For secondary amenorrhea, consider the compartmental approach — hypothalamus, pituitary, ovary, uterus/outflow
- Step 4: Check thyroid-stimulating hormone and prolactin in all cases
Secondary Amenorrhea (More Common)
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Pregnancy | Must always exclude | Amenorrhea with breast tenderness, nausea, fatigue; positive pregnancy test |
| COMMON | Polycystic Ovary Syndrome | 30-40% of secondary amenorrhea | Oligomenorrhea more common than amenorrhea; hyperandrogenism; obesity; insulin resistance |
| COMMON | Functional Hypothalamic Amenorrhea | 20-35% | Related to stress, weight loss, excessive exercise, eating disorders; low or normal gonadotropins |
| COMMON | Hyperprolactinemia | 15-20% | Galactorrhea; headache; visual field defects if macroadenoma; may be drug-induced |
| LESS COMMON | Premature Ovarian Insufficiency | 10-15% | Amenorrhea before age 40; vasomotor symptoms; elevated follicle-stimulating hormone |
| LESS COMMON | Thyroid Dysfunction | 5-10% | Symptoms of hypothyroidism or hyperthyroidism; abnormal thyroid-stimulating hormone |
| LESS COMMON | Asherman Syndrome (Intrauterine Adhesions) | 5-7% | Amenorrhea following uterine instrumentation (dilation and curettage, hysteroscopy); cyclic pain without bleeding |
| UNCOMMON | Pituitary Tumor (Non-Prolactinoma) | Less than 5% | Headache; visual field defects; may have other hormone deficiencies |
| UNCOMMON | Sheehan Syndrome | Rare | Pituitary necrosis following postpartum hemorrhage; failure of lactation; multiple hormone deficiencies |
Primary Amenorrhea
| Category | Condition | Key Features |
|---|---|---|
| With Breast Development (Estrogen Present) | Müllerian Agenesis (Mayer-Rokitansky-Küster-Hauser Syndrome) | Normal secondary sexual characteristics; absent or rudimentary uterus; normal female karyotype (46,XX) |
| With Breast Development | Complete Androgen Insensitivity Syndrome | Female phenotype with breast development; absent pubic/axillary hair; blind vaginal pouch; 46,XY karyotype |
| With Breast Development | Imperforate Hymen or Transverse Vaginal Septum | Cyclic pelvic pain; bulging hymen; hematocolpos on examination |
| Without Breast Development (No Estrogen) | Turner Syndrome (45,X) | Short stature; webbed neck; shield chest; streak gonads; elevated gonadotropins |
| Without Breast Development | Kallmann Syndrome | Hypogonadotropic hypogonadism; anosmia or hyposmia; low gonadotropins |
| Without Breast Development | Constitutional Delay of Puberty | Family history of late puberty; bone age delayed; eventual spontaneous puberty |
Irregular Bleeding (Metrorrhagia/Intermenstrual Bleeding)
| Probability | Condition | Key Features | Next Step |
|---|---|---|---|
| COMMON | Hormonal Contraception (Breakthrough Bleeding) | Irregular bleeding in first 3 months of use; missed pills; drug interactions | Reassurance if new user; check compliance; exclude other causes if persistent |
| COMMON | Ovulatory Dysfunction | Unpredictable timing; variable flow; associated conditions (polycystic ovary syndrome, perimenopause) | Endometrial assessment if prolonged or age over 45 |
| COMMON | Endometrial Polyps | Intermenstrual spotting; postcoital bleeding; may be asymptomatic | Transvaginal ultrasound; saline infusion sonography; hysteroscopy |
| LESS COMMON | Cervical Pathology (Polyps, Ectropion, Cervicitis) | Postcoital bleeding; intermenstrual spotting; visible lesion on speculum | Speculum examination; cervical cytology; colposcopy if abnormal |
| LESS COMMON | Pregnancy-Related (Early Pregnancy, Ectopic) | Bleeding after missed period; pelvic pain; positive pregnancy test | Urgent pregnancy test; ultrasound; serial beta-human chorionic gonadotropin |
| UNCOMMON BUT SERIOUS | Cervical Carcinoma | Postcoital bleeding; persistent intermenstrual bleeding; abnormal discharge; visible cervical lesion | Urgent colposcopy and biopsy; staging if confirmed |
| UNCOMMON BUT SERIOUS | Endometrial Carcinoma | Irregular bleeding especially in older or high-risk women; postmenopausal bleeding | Endometrial biopsy; hysteroscopy |
Anatomical Approach to Menstrual Change
Hypothalamus/Pituitary
Functional hypothalamic amenorrhea
Hyperprolactinemia
Pituitary adenoma
Sheehan syndrome
Kallmann syndrome
Medications affecting dopamine
Ovary
Polycystic ovary syndrome
Premature ovarian insufficiency
Turner syndrome
Ovarian tumors (rare)
Chemotherapy/radiation damage
Autoimmune oophoritis
Uterus
Fibroids (leiomyomata)
Adenomyosis
Endometrial polyps
Endometrial hyperplasia
Endometrial carcinoma
Asherman syndrome
Outflow Tract/Systemic
Cervical pathology (polyps, cancer)
Imperforate hymen
Vaginal septum
Thyroid dysfunction
Coagulopathy
Chronic disease (renal, hepatic)
Age-Based Differential Considerations
| Age Group | Most Common Causes | Special Considerations |
|---|---|---|
| Adolescence (Menarche to 18 years) | Anovulatory cycles (physiological immaturity of hypothalamic-pituitary-ovarian axis); coagulopathy; polycystic ovary syndrome; pregnancy | Screen for coagulopathy if heavy bleeding from menarche; anovulation normal for first 2-3 years post-menarche |
| Reproductive Years (18-40 years) | Pregnancy-related; structural causes (fibroids, polyps, adenomyosis); polycystic ovary syndrome; contraception-related | Always exclude pregnancy; contraceptive history essential; consider fertility implications |
| Perimenopause (40-50 years) | Anovulatory cycles; fibroids; adenomyosis; endometrial hyperplasia; early malignancy | Lower threshold for endometrial sampling; increased malignancy risk; distinguish from normal perimenopausal changes |
| Postmenopause (After 12 months amenorrhea) | Endometrial atrophy (most common); endometrial polyps; endometrial hyperplasia; endometrial carcinoma | Any bleeding requires investigation to exclude malignancy; endometrial carcinoma until proven otherwise |
Drug-Induced Menstrual Changes
| Drug or Drug Class | Mechanism | Type of Menstrual Change | Time to Resolution After Stopping |
|---|---|---|---|
| Antipsychotics (haloperidol, risperidone) | Dopamine antagonism causing hyperprolactinemia | Oligomenorrhea, amenorrhea, galactorrhea | Weeks to months; depends on drug half-life |
| Metoclopramide, domperidone | Dopamine antagonism causing hyperprolactinemia | Oligomenorrhea, amenorrhea | Days to weeks |
| Anticoagulants (warfarin, direct oral anticoagulants) | Impaired hemostasis | Heavy menstrual bleeding, prolonged bleeding | Days after discontinuation or dose reduction |
| Selective serotonin reuptake inhibitors | Platelet dysfunction; possible prolactin effects | Increased bleeding; occasionally irregular cycles | Weeks |
| Corticosteroids (chronic use) | Hypothalamic-pituitary-ovarian axis suppression | Oligomenorrhea, amenorrhea | Months; may require axis recovery |
| Chemotherapy agents | Gonadotoxicity; ovarian damage | Oligomenorrhea, amenorrhea, premature ovarian insufficiency | Variable; may be permanent |
| Tamoxifen | Partial estrogen agonist effect on endometrium | Irregular bleeding; increased polyp, hyperplasia, and malignancy risk | Weeks to months after stopping |
| Progestogen-only contraceptives | Endometrial atrophy with unstable blood vessels | Irregular bleeding, amenorrhea (variable pattern) | Months; depot forms take longer |
| Copper intrauterine device | Local inflammatory response; increased prostaglandins | Heavy menstrual bleeding, dysmenorrhea | Immediate after removal |
| Valproic acid | May cause polycystic ovary syndrome-like features | Oligomenorrhea, amenorrhea, weight gain | Months; effects may be persistent |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Heavy bleeding since menarche with easy bruising | Von Willebrand disease or other coagulopathy | Complete blood count, coagulation screen, von Willebrand panel |
| Irregular periods with hirsutism and acne | Polycystic ovary syndrome | Testosterone, sex hormone-binding globulin, pelvic ultrasound |
| Amenorrhea with galactorrhea | Hyperprolactinemia | Prolactin level, pituitary MRI if elevated |
| Amenorrhea with weight loss and excessive exercise | Functional hypothalamic amenorrhea | Follicle-stimulating hormone, luteinizing hormone, estradiol, thyroid-stimulating hormone |
| Amenorrhea with hot flashes in woman under 40 | Premature ovarian insufficiency | Follicle-stimulating hormone (repeated), estradiol, anti-Müllerian hormone |
| Heavy, regular periods with enlarged, irregular uterus | Uterine fibroids | Pelvic ultrasound; consider MRI for surgical planning |
| Heavy, painful periods with tender, boggy uterus | Adenomyosis | Transvaginal ultrasound; MRI if diagnosis uncertain |
| Intermenstrual and postcoital bleeding | Cervical or endometrial polyp; cervical pathology | Speculum examination, cervical cytology, pelvic ultrasound, hysteroscopy |
| Postmenopausal bleeding | Endometrial cancer until proven otherwise | Urgent transvaginal ultrasound, endometrial biopsy |
| Amenorrhea after uterine instrumentation | Asherman syndrome (intrauterine adhesions) | Hysteroscopy; saline infusion sonography |
| Irregular bleeding in obese woman with anovulation | Endometrial hyperplasia (high risk) | Endometrial biopsy; transvaginal ultrasound |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Investigation of menstrual change should be guided by the clinical presentation, patient age, and risk factors. A stepwise approach avoids unnecessary testing while ensuring serious pathology is not missed.
First-Line Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Urine Pregnancy Test | Exclude pregnancy in any woman of reproductive age | Positive result mandates pregnancy-focused evaluation | Perform before any other investigation; highly sensitive from first day of missed period |
| Full Blood Count | Assess for anemia and blood loss severity | Hemoglobin, mean corpuscular volume (microcytic suggests iron deficiency), platelet count | Hemoglobin less than 120 g/L indicates anemia; microcytosis with low ferritin confirms iron deficiency |
| Ferritin | Assess iron stores | Low ferritin (less than 30 μg/L) indicates iron deficiency even with normal hemoglobin | May be falsely elevated in inflammation; check C-reactive protein if uncertain |
| Thyroid-Stimulating Hormone | Screen for thyroid dysfunction | Elevated: hypothyroidism; Suppressed: hyperthyroidism | Thyroid dysfunction is common and easily treatable cause of menstrual change |
Additional Investigations Based on Presentation
For Amenorrhea or Oligomenorrhea
| Investigation | Purpose | Interpretation |
|---|---|---|
| Prolactin | Screen for hyperprolactinemia | Mild elevation (up to 50 μg/L): may be stress, drugs, or microprolactinoma; greater than 100 μg/L: strongly suggests prolactinoma; greater than 200 μg/L: almost certainly macroprolactinoma |
| Follicle-Stimulating Hormone and Luteinizing Hormone | Assess pituitary-ovarian axis; differentiate hypogonadotropic from hypergonadotropic states | Elevated follicle-stimulating hormone (greater than 25 IU/L): ovarian failure; Low/normal with low estradiol: hypothalamic/pituitary cause; Luteinizing hormone to follicle-stimulating hormone ratio greater than 2: suggests polycystic ovary syndrome |
| Estradiol | Assess ovarian estrogen production | Low levels indicate hypoestrogenism; helps differentiate cause of amenorrhea |
| Testosterone and Sex Hormone-Binding Globulin | Assess for hyperandrogenism | Calculate free androgen index; elevated in polycystic ovary syndrome; markedly elevated testosterone (greater than 5 nmol/L) suggests androgen-secreting tumor |
For Suspected Coagulopathy
Initial Coagulation Screen
- Prothrombin time and activated partial thromboplastin time: Prolonged values suggest clotting factor deficiency
- Platelet count: Thrombocytopenia can cause heavy bleeding
- Blood film: Assess platelet morphology
Von Willebrand Disease Screening
- Von Willebrand factor antigen: Measures quantity of von Willebrand factor
- Von Willebrand factor activity (Ristocetin cofactor): Measures function
- Factor VIII: Often reduced in von Willebrand disease
- Note: Levels fluctuate with menstrual cycle and stress; may need repeat testing
When to Screen for Coagulopathy
Consider coagulopathy screening in women with:
- Heavy menstrual bleeding since menarche
- Personal history of bleeding complications (dental extraction, surgery, childbirth)
- Family history of bleeding disorder
- Easy bruising or mucosal bleeding
- Postpartum hemorrhage
The prevalence of von Willebrand disease in women with heavy menstrual bleeding is approximately 13% — significantly higher than the general population.
Imaging Studies
Pelvic Ultrasound
| Modality | Indications | What It Detects | Limitations |
|---|---|---|---|
| Transvaginal Ultrasound | First-line imaging for most presentations; abnormal uterine bleeding; pelvic mass; suspected structural pathology | Fibroids (size, number, location); endometrial thickness and abnormalities; ovarian cysts and masses; adenomyosis features; polyps (may be seen) | Operator-dependent; small polyps may be missed; cannot definitively distinguish hyperplasia from cancer |
| Transabdominal Ultrasound | Virginal patients; large pelvic masses; overview of pelvis | Large fibroids; ovarian masses; general pelvic anatomy | Less detailed than transvaginal; requires full bladder |
| Saline Infusion Sonography (Sonohysterography) | Suspected intrauterine pathology; abnormal endometrial appearance on standard ultrasound | Endometrial polyps; submucosal fibroids; intrauterine adhesions (Asherman syndrome) | Invasive; requires speculum and catheter; not suitable during active bleeding or infection |
Endometrial Thickness Interpretation
Key Thresholds:
- Postmenopausal women with bleeding: Endometrial thickness greater than 4 mm requires further investigation (biopsy or hysteroscopy)
- Postmenopausal women without bleeding: Thickened endometrium is less concerning but may warrant follow-up
- Premenopausal women: Endometrial thickness varies with cycle (thinnest during menstruation, thickest in secretory phase up to 14 mm); threshold less useful
- Women on tamoxifen: Endometrium often appears thickened due to subendometrial changes; standard thresholds do not apply
Other Imaging Modalities
| Modality | Indications | Advantages |
|---|---|---|
| Pelvic MRI | Fibroid mapping before surgery; adenomyosis confirmation; staging of gynecological malignancy; Müllerian anomalies | Superior soft tissue resolution; precise fibroid location and size; distinguishes adenomyosis from fibroids |
| Pituitary MRI | Hyperprolactinemia; suspected pituitary tumor; visual field defects with amenorrhea | Detects microadenomas and macroadenomas; assesses optic chiasm compression |
Endometrial Sampling
Indications for Endometrial Biopsy
- All women with postmenopausal bleeding
- Women over 45 years with abnormal uterine bleeding
- Women under 45 with risk factors for endometrial hyperplasia or cancer: obesity, polycystic ovary syndrome, chronic anovulation, tamoxifen use, family history (Lynch syndrome)
- Thickened endometrium on ultrasound (greater than 4 mm postmenopausal)
- Failed medical management of abnormal bleeding
- Persistent intermenstrual bleeding
| Method | Technique | Advantages | Limitations |
|---|---|---|---|
| Pipelle Endometrial Biopsy | Outpatient procedure; thin plastic catheter inserted through cervix | Quick; well-tolerated; no anesthesia needed; sensitivity approximately 90% for endometrial cancer | May miss focal lesions (polyps); sampling error; inadequate sample in atrophic endometrium |
| Hysteroscopy with Biopsy | Direct visualization of uterine cavity with targeted biopsy | Visualizes cavity directly; can biopsy focal lesions; can remove polyps; highest diagnostic accuracy | More invasive; may require anesthesia; higher cost; risk of perforation |
| Dilation and Curettage | Cervical dilation followed by endometrial curettage | Samples larger area; therapeutic effect in some cases | Requires anesthesia; blind procedure; may miss focal lesions; risk of Asherman syndrome |
Targeted Investigation Pathways
Suspected Polycystic Ovary Syndrome
Diagnostic Investigations
- Testosterone: Mildly elevated (typically less than 5 nmol/L)
- Sex hormone-binding globulin: Often low
- Free androgen index: Elevated (testosterone × 100 ÷ sex hormone-binding globulin)
- Luteinizing hormone and follicle-stimulating hormone: Luteinizing hormone often elevated; luteinizing hormone to follicle-stimulating hormone ratio greater than 2
- Pelvic ultrasound: Polycystic ovarian morphology (≥20 follicles per ovary or ovarian volume greater than 10 mL)
Metabolic Assessment
- Fasting glucose and HbA1c: Screen for diabetes
- Oral glucose tolerance test: If high risk
- Lipid profile: Often dyslipidemia present
- Liver function tests: Before starting metformin if planned
- Blood pressure: Cardiovascular risk assessment
Suspected Premature Ovarian Insufficiency
Diagnostic Criteria
- Follicle-stimulating hormone: Greater than 25 IU/L on two occasions, 4-6 weeks apart
- Estradiol: Low (postmenopausal range)
- Anti-Müllerian hormone: Low or undetectable (indicates reduced ovarian reserve)
Etiological Investigation
- Karyotype: Exclude Turner syndrome mosaicism, fragile X premutation
- Fragile X (FMR1) testing: If family history or no cause identified
- Adrenal antibodies: Screen for autoimmune adrenalitis (Addison disease risk)
- Thyroid antibodies: Associated autoimmune thyroid disease
Empiric Treatment Trials as Diagnostic Tools
Sequential Empiric Therapy Approach
When the cause of abnormal uterine bleeding is uncertain after initial investigation, response to empiric treatment can provide diagnostic information:
- Trial of combined hormonal contraceptive or cyclic progestin: Response suggests ovulatory dysfunction or primary endometrial hemostatic disorder
- Trial of tranexamic acid: Improvement suggests increased fibrinolysis as contributing factor
- Trial of NSAIDs (mefenamic acid, naproxen): Response suggests prostaglandin-mediated heavy bleeding
- Levonorgestrel intrauterine system: Both diagnostic and therapeutic; response supports non-structural cause
Note: Empiric treatment does not replace the need for endometrial sampling in high-risk patients.
Investigation Summary by Presentation
| Presentation | First-Line Investigations | Second-Line Investigations |
|---|---|---|
| Heavy Menstrual Bleeding | Pregnancy test, full blood count, ferritin, thyroid-stimulating hormone, transvaginal ultrasound | Coagulation screen (if from menarche), endometrial biopsy (if over 45 or risk factors), saline infusion sonography/hysteroscopy |
| Secondary Amenorrhea | Pregnancy test, follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin, thyroid-stimulating hormone | Testosterone/sex hormone-binding globulin (if hyperandrogenism), pelvic ultrasound, pituitary MRI (if elevated prolactin), progestogen withdrawal test |
| Primary Amenorrhea | Follicle-stimulating hormone, luteinizing hormone, estradiol, thyroid-stimulating hormone, prolactin, pelvic ultrasound | Karyotype, pelvic MRI (if uterine anomaly suspected), testosterone (if virilization) |
| Irregular Bleeding | Pregnancy test, thyroid-stimulating hormone, pelvic ultrasound, cervical cytology if due | Endometrial biopsy (if over 45 or risk factors), hysteroscopy, sexually transmitted infection screen |
| Postmenopausal Bleeding | Transvaginal ultrasound (endometrial thickness), endometrial biopsy | Hysteroscopy with biopsy (if biopsy inadequate or negative with persistent symptoms), cervical cytology |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Hemodynamic instability (tachycardia, hypotension, orthostatic symptoms) with heavy bleeding | EMERGENT | Intravenous access, fluid resuscitation, cross-match blood, urgent gynecology referral, consider tranexamic acid and high-dose progestogens |
| Positive pregnancy test with bleeding and abdominal pain | EMERGENT | Urgent ultrasound to exclude ectopic pregnancy; if unstable, immediate surgical consultation |
| Heavy bleeding with fever and pelvic pain | EMERGENT | Exclude septic abortion or pelvic inflammatory disease; blood cultures, broad-spectrum antibiotics, gynecology referral |
| Postmenopausal bleeding | URGENT | Refer for transvaginal ultrasound and endometrial biopsy within 2 weeks; endometrial cancer until proven otherwise |
| New irregular bleeding in woman over 45 years | URGENT | Pelvic ultrasound and endometrial biopsy within 2-4 weeks; exclude endometrial pathology |
| Intermenstrual or postcoital bleeding with visible cervical lesion | URGENT | Urgent colposcopy referral; suspect cervical malignancy |
| Amenorrhea with severe headache or visual field defect | URGENT | Check prolactin urgently; MRI pituitary if elevated or neurological symptoms; pituitary macroadenoma with compression |
| Heavy menstrual bleeding causing iron deficiency anemia | SOON | Start iron replacement; initiate medical management; investigate within 4-6 weeks |
| Irregular periods in young woman with hyperandrogenism | ROUTINE | Evaluate for polycystic ovary syndrome; metabolic screening; routine gynecology or endocrine referral |
| Breakthrough bleeding on hormonal contraception (first 3 months) | ROUTINE | Reassurance; check compliance; exclude sexually transmitted infection if at risk; review in 3 months |
Step 2: Classify the Presentation
Heavy Bleeding
Regular cycle, excessive flow
→ Proceed to Algorithm A
Absent Periods
Amenorrhea (primary or secondary)
→ Proceed to Algorithm B
Irregular Bleeding
Unpredictable timing or intermenstrual
→ Proceed to Algorithm C
Step 3: Follow the Appropriate Algorithm
Algorithm A: Heavy Menstrual Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Heavy bleeding since menarche + easy bruising + family history | Coagulopathy (von Willebrand disease) | Coagulation screen, von Willebrand panel; refer to hematology; tranexamic acid, consider desmopressin |
| Heavy regular periods + enlarged irregular uterus + pressure symptoms | Uterine fibroids | Pelvic ultrasound; medical management (tranexamic acid, levonorgestrel intrauterine system); consider surgical options if failed |
| Heavy painful periods + uniformly enlarged tender uterus + worsening dysmenorrhea | Adenomyosis | Transvaginal ultrasound (MRI if uncertain); levonorgestrel intrauterine system first-line; consider GnRH analogues or hysterectomy |
| Heavy periods + normal uterus + normal investigations | Primary endometrial hemostatic disorder | Trial of tranexamic acid or NSAIDs; if ineffective, levonorgestrel intrauterine system or combined hormonal contraceptive |
| Heavy periods since copper intrauterine device insertion | Copper intrauterine device-related bleeding | Exclude other pathology; offer removal and alternative contraception; consider switch to levonorgestrel intrauterine system |
| Heavy periods + anticoagulant therapy | Anticoagulant-related bleeding | Review anticoagulation indication and intensity; tranexamic acid if not contraindicated; levonorgestrel intrauterine system; liaise with anticoagulation service |
| Heavy irregular bleeding + obesity + age over 45 | Endometrial hyperplasia (high risk) | Urgent endometrial biopsy; if hyperplasia confirmed, progestogen treatment or hysterectomy depending on atypia |
Algorithm B: Amenorrhea
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Amenorrhea + positive pregnancy test | Pregnancy | Confirm intrauterine pregnancy with ultrasound; antenatal care or options counseling |
| Oligomenorrhea/amenorrhea + hirsutism + obesity + acanthosis nigricans | Polycystic ovary syndrome | Testosterone, sex hormone-binding globulin, pelvic ultrasound; metabolic screen; lifestyle modification, metformin if insulin resistant, cyclic progestogens or combined oral contraceptive |
| Amenorrhea + galactorrhea ± headache | Hyperprolactinemia | Prolactin level; if elevated, pituitary MRI; dopamine agonist (cabergoline) if prolactinoma; review medications |
| Amenorrhea + low body mass index + excessive exercise + stress | Functional hypothalamic amenorrhea | Follicle-stimulating hormone, luteinizing hormone, estradiol (all low/normal); address underlying cause; nutritional rehabilitation; hormone replacement if prolonged hypoestrogenism |
| Amenorrhea + hot flashes + age under 40 + elevated follicle-stimulating hormone | Premature ovarian insufficiency | Repeat follicle-stimulating hormone in 4-6 weeks; karyotype; fragile X testing; hormone replacement therapy until average age of menopause |
| Amenorrhea after uterine instrumentation + cyclic pain | Asherman syndrome | Saline infusion sonography or hysteroscopy; adhesiolysis if confirmed; estrogen therapy post-procedure |
| Amenorrhea + fatigue + weight gain + cold intolerance | Hypothyroidism | Thyroid-stimulating hormone, free T4; levothyroxine replacement if confirmed |
| Primary amenorrhea + normal breast development + absent uterus on ultrasound | Müllerian agenesis or androgen insensitivity syndrome | Karyotype; MRI pelvis; multidisciplinary management; psychological support |
Algorithm C: Irregular Bleeding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Irregular bleeding + recently started hormonal contraception (less than 3 months) | Breakthrough bleeding (adjustment phase) | Reassurance; check compliance; continue for 3 months; exclude sexually transmitted infection if at risk |
| Irregular bleeding + hormonal contraception greater than 3 months + missed pills or interactions | Reduced contraceptive efficacy | Review compliance and drug interactions; consider alternative method; exclude pregnancy |
| Intermenstrual spotting + postcoital bleeding + normal cervix | Endometrial or cervical polyp | Pelvic ultrasound; saline infusion sonography; hysteroscopic polypectomy |
| Postcoital bleeding + visible cervical lesion or friability | Cervical pathology (ectropion, polyp, or malignancy) | Cervical cytology; colposcopy referral; biopsy of suspicious lesions |
| Irregular heavy bleeding + anovulatory features (age extremes, polycystic ovary syndrome) | Ovulatory dysfunction | Endometrial biopsy if over 45 or risk factors; cyclic progestogens or combined hormonal contraceptive to regulate cycle |
| Any bleeding after 12 months of amenorrhea (postmenopausal) | Endometrial pathology until proven otherwise | Urgent transvaginal ultrasound; endometrial biopsy if thickness greater than 4 mm or any bleeding persists |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient is bleeding heavily right now and feeling faint | Lie patient flat, check vital signs, establish intravenous access, give fluids, check hemoglobin urgently | Tranexamic acid 1g intravenously; high-dose oral progestogen (medroxyprogesterone acetate 20mg three times daily or norethisterone 5mg three times daily); urgent gynecology referral |
| Endometrial biopsy shows hyperplasia without atypia | Explain diagnosis; start progestogen therapy (levonorgestrel intrauterine system preferred, or oral progestogens) | Repeat endometrial biopsy at 6 months; if persistent, consider hysteroscopy or referral |
| Endometrial biopsy shows hyperplasia with atypia | Urgent gynecology oncology referral; explain risk of concurrent or progression to carcinoma | Hysterectomy usually recommended; fertility-sparing progestogen therapy only in selected cases with close surveillance |
| Prolactin is mildly elevated (25-50 μg/L) | Review medications (antipsychotics, metoclopramide); repeat fasting prolactin; check thyroid-stimulating hormone | If persistent elevation with no drug cause, pituitary MRI; if normal MRI and mild elevation, may observe with repeat prolactin |
| Prolactin is markedly elevated (greater than 100 μg/L) | Pituitary MRI to assess for prolactinoma; visual field testing if macroadenoma | Dopamine agonist therapy (cabergoline first-line); monitor prolactin and MRI response |
| Follicle-stimulating hormone is elevated in woman under 40 | Repeat follicle-stimulating hormone and estradiol in 4-6 weeks to confirm | If confirmed, diagnose premature ovarian insufficiency; karyotype, fragile X, autoimmune screen; hormone replacement therapy; discuss fertility implications |
| Patient wants to conceive but has polycystic ovary syndrome and anovulation | Optimize weight (if overweight); preconception folic acid; baseline investigations | Refer to fertility service; ovulation induction with letrozole or clomiphene; metformin as adjunct if insulin resistant |
| Medical management of heavy bleeding has failed | Review diagnosis — has structural pathology been excluded? Has levonorgestrel intrauterine system been tried? | Refer for surgical options: hysteroscopic procedures (polypectomy, myomectomy, ablation) or hysterectomy depending on pathology and fertility wishes |
| Adolescent has heavy periods from menarche | Full blood count and ferritin; coagulation screen and von Willebrand panel | If coagulopathy excluded, reassurance that anovulatory cycles common initially; tranexamic acid or combined oral contraceptive if needed; hematology referral if coagulopathy found |
Troubleshooting Refractory Menstrual Problems
Ask These Questions When Treatment Fails
- Is the diagnosis correct? — Re-evaluate; consider missed structural pathology (small polyps, adenomyosis), coagulopathy, or thyroid dysfunction
- Was the treatment given adequate time? — Levonorgestrel intrauterine system takes 3-6 months for full effect; hormonal treatments need at least 3 cycles
- Was compliance adequate? — Oral medications require consistent use; check understanding and barriers
- Are there multiple contributing factors? — Fibroids plus coagulopathy, adenomyosis plus polyps, polycystic ovary syndrome plus thyroid dysfunction
- Has the clinical situation changed? — New pregnancy, fibroid growth, development of hyperplasia
- Have patient priorities changed? — Fertility desires, tolerance of side effects, preference for definitive treatment
- Is specialist referral needed? — Gynecology, hematology, endocrinology, or reproductive medicine depending on situation
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Always exclude pregnancy first: A urine pregnancy test should be performed in any woman of reproductive age presenting with menstrual change, regardless of reported sexual activity or contraceptive use. Ectopic pregnancy can be life-threatening.
Postmenopausal bleeding is endometrial cancer until proven otherwise: Any bleeding after 12 months of amenorrhea requires urgent investigation with transvaginal ultrasound and endometrial biopsy. Do not attribute to “hormonal changes” without investigation.
Screen for coagulopathy in adolescents with heavy bleeding from menarche: Von Willebrand disease affects up to 13% of women with heavy menstrual bleeding but is frequently undiagnosed. Ask about bruising, bleeding from dental work, and family history.
The levonorgestrel intrauterine system is first-line for heavy menstrual bleeding: It reduces menstrual blood loss by 90% and is more effective than oral treatments. It should be offered to all eligible women before considering surgery.
Irregular bleeding in anovulatory women requires endometrial protection: Chronic anovulation with unopposed estrogen (polycystic ovary syndrome, obesity, perimenopause) increases endometrial hyperplasia and cancer risk. Cyclic progestogens or combined hormonal contraceptives provide protection.
Thyroid dysfunction is a common, treatable cause: Both hypothyroidism and hyperthyroidism can cause menstrual disturbance. Thyroid-stimulating hormone should be checked in all women with menstrual change — it’s inexpensive and the diagnosis is easily treated.
Quality of life defines heavy menstrual bleeding, not arbitrary measurements: If bleeding interferes with a woman’s physical, social, or emotional wellbeing, it warrants treatment regardless of measured blood loss.
Multiple causes often coexist: A woman may have fibroids AND adenomyosis, or polycystic ovary syndrome AND a coagulopathy. Incomplete response to treatment should prompt consideration of additional contributing factors.
Critical Pitfalls to Avoid
Assuming amenorrhea is “just stress” without investigation: While functional hypothalamic amenorrhea is common, always exclude pregnancy, hyperprolactinemia, thyroid dysfunction, and premature ovarian insufficiency with appropriate tests before attributing amenorrhea to stress.
Forgetting to check medications as a cause: Antipsychotics, metoclopramide, anticoagulants, and many other drugs affect menstruation. Always take a thorough medication history including over-the-counter and herbal supplements.
Reassuring perimenopausal women without investigation: While irregular cycles are expected in perimenopause, women over 45 with heavy or irregular bleeding are at increased risk of endometrial pathology. Lower your threshold for endometrial biopsy in this age group.
Missing endometrial hyperplasia risk in young obese women: Endometrial cancer can occur in women in their 20s and 30s if they have chronic anovulation and obesity. Do not assume young age is protective — investigate appropriately.
Relying solely on ultrasound to exclude endometrial pathology: Transvaginal ultrasound can miss small polyps and cannot distinguish hyperplasia from cancer. Endometrial biopsy is required for histological diagnosis in high-risk patients.
Stopping investigation after finding fibroids: Fibroids are very common and may be incidental. Ensure they are the actual cause of symptoms (submucosal location) and exclude coexisting pathology, especially in women with risk factors for endometrial disease.
Delaying investigation of intermenstrual or postcoital bleeding: These symptoms may indicate cervical or endometrial pathology including malignancy. Always perform speculum examination and arrange appropriate investigation promptly.
Not addressing iron deficiency: Women with heavy menstrual bleeding often have significant iron deficiency that impairs quality of life. Always check ferritin and treat iron deficiency, not just anemia.
Key Takeaways
- Pregnancy test first: Always exclude pregnancy in any woman of reproductive age with menstrual change before proceeding with other investigations.
- Use the PALM-COEIN system: Categorize causes as structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) or non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified) for systematic evaluation.
- Age guides investigation intensity: Lower threshold for endometrial sampling in women over 45, those with risk factors (obesity, anovulation, tamoxifen), and anyone with postmenopausal bleeding.
- History predicts pathology: Heavy regular periods suggest structural causes; irregular bleeding suggests ovulatory dysfunction; bleeding from menarche with bruising suggests coagulopathy.
- Thyroid and prolactin are easily treatable: Always check thyroid-stimulating hormone; add prolactin if amenorrhea or galactorrhea. These are common, reversible causes of menstrual disturbance.
- The levonorgestrel intrauterine system is highly effective: It reduces menstrual blood loss by 90% and should be offered as first-line treatment for heavy menstrual bleeding before surgical options.
- Protect the endometrium in anovulatory women: Chronic unopposed estrogen exposure increases endometrial hyperplasia and cancer risk. Provide progestogen protection through cyclic treatment, combined contraceptives, or levonorgestrel intrauterine system.
- Consider multiple diagnoses: Incomplete treatment response should prompt re-evaluation for additional contributing factors — structural pathology, coagulopathy, thyroid dysfunction, or incorrect initial diagnosis.
- Investigate urgently when indicated: Postmenopausal bleeding, suspected pregnancy complications, hemodynamic instability, and visible cervical lesions require urgent assessment — do not delay.
- Patient priorities matter: Treatment should be guided by the patient’s symptoms, quality of life impact, fertility desires, and preferences. A woman-centered approach improves outcomes and satisfaction.
Quick Reference Algorithm
Systematic Approach to Menstrual Change:
- Exclude pregnancy — Urine pregnancy test in all women of reproductive age
- Identify red flags — Postmenopausal bleeding, hemodynamic instability, pregnancy with bleeding, severe pain with fever → urgent management
- Classify the change — Heavy bleeding, absent periods, or irregular bleeding
- Take focused history — Use “PERIODS” mnemonic; quantify bleeding impact; identify associated symptoms; medication and contraceptive history
- Perform targeted examination — General (body mass index, pallor, hyperandrogenism, thyroid), abdominal, pelvic when indicated
- Order first-line investigations — Full blood count, ferritin, thyroid-stimulating hormone; add prolactin and gonadotropins for amenorrhea
- Arrange imaging — Transvaginal ultrasound for most presentations; saline infusion sonography if intrauterine pathology suspected
- Obtain tissue diagnosis when indicated — Endometrial biopsy for women over 45, risk factors, postmenopausal bleeding, or failed treatment
- Initiate treatment — Address underlying cause; levonorgestrel intrauterine system for heavy bleeding; cyclic progestogens for anovulation; treat iron deficiency
- Review and follow up — Assess treatment response; re-evaluate if refractory; refer for specialist management when needed